SIGA Technologies (NASDAQ:SIGA) Stock Price Up 10.6%
SIGA Technologies (NASDAQ:SIGA) Stock Price Up 10.6%
SIGA Technologies, Inc. (NASDAQ:SIGA – Get Rating)'s stock price was up 10.6% during trading on Friday . The stock traded as high as $9.19 and last traded at $9.15. Approximately 52,632 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 1,258,051 shares. The stock had previously closed at $8.27.
SIGA 科技股份有限公司（納斯達克：SIGA-獲得評級）的股票價格上漲了 10.6％ 在星期五交易期間。該股票交易高達 9.19 美元，最後交易價為 9.15 美元。大約 52,632 股股票在中間交易期間轉手，較每日 1258,051 股的平均成交量下降了 96%。該股票之前已收盤 8.27 美元。
SIGA Technologies Trading Up 11.4 %
SIGA 技術交易上漲 11.4%
The firm has a market cap of $672.51 million, a price-to-earnings ratio of 6.35 and a beta of 0.73. The stock's 50 day moving average is $10.90 and its 200 day moving average is $12.48.
該公司的市值為 672.51 萬美元，價格與收益比為 6.35，貝塔值為 0.73。該股票的 50 日移動平均線為 10.90 美元，其 200 日移動平均線為 12.48 美元。
SIGA Technologies (NASDAQ:SIGA – Get Rating) last released its earnings results on Thursday, August 4th. The company reported $0.03 earnings per share for the quarter. The firm had revenue of $16.67 million during the quarter. SIGA Technologies had a return on equity of 48.79% and a net margin of 48.67%. On average, equities research analysts predict that SIGA Technologies, Inc. will post 0.66 EPS for the current year.
SIGA 技術（NASDAQ：SIGA-獲取評級）最近一次發布了 8 月 4 日（週四）的盈利業績。該公司報告了本季度每股盈利 0.03 美元。該公司在本季度的收入為 1667 萬美元。SIGA 科技的股本回報率為 48.79%，淨利潤率為 48.67％。平均而言，股票研究分析師預測 SIGA 科技股份有限公司將在本年度公布 0.66 每股盈利。
Institutional Investors Weigh In On SIGA Technologies
機構投資者權衡 SIGA 技術
SIGA Technologies Company Profile
SIGA 科技公司簡介
(Get Rating)
(取得評分)
SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.
SIGA Technologies, Inc 是一家商業階段的製藥公司，專注於美國的健康安全和傳染病市場。其主導產品是 TPOXX，一種口服配方抗病毒藥物，用於治療由天花病毒引起的人類天花病。SIGA Technologies 公司與 Cipla Theraptics 建立了戰略合作夥伴關係，旨在提供持續的創新並獲得主要針對生物威脅的抗菌藥物。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on SIGA Technologies (SIGA)
- MarketBeat: Week in Review 10/31-11/4
- Is Hershey's a Sweet Stock to Buy After a Post-Earnings Dip?
- Datadog Doesn't Belong In The Doghouse
- Nikola Shares Fall Even As EV Maker Beats Q3 Expectations
- Mixed Results Actually Bring More Optimism than Risk for AMD
- 獲取有關 SIGA 技術研究報告的免費副本
- 市場節拍：評論中的一周
- 收益後下跌後，好時是否可以買到甜美股票？
- 達達多格不屬於狗屋
- 尼古拉股票下跌，即使電動汽車製造商勝過第三季度預期
- 混合結果實際上比 AMD 的風險帶來更樂觀
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 SIGA 技術的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 SIGA 技術和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。